Home » Stocks » Aprea Therapeutics

Aprea Therapeutics, Inc. (APRE)

Stock Price: $26.00 USD -0.78 (-2.91%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 550.86M
Revenue (ttm) n/a
Net Income (ttm) -45.09M
Shares Out 21.19M
EPS (ttm) -26.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $26.00
Previous Close $26.78
Change ($) -0.78
Change (%) -2.91%
Day's Open 26.40
Day's Range 25.04 - 27.09
Day's Volume 58,513
52-Week Range 21.22 - 53.11

More Stats

Market Cap 550.86M
Enterprise Value 438.18M
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 21.19M
Float 12.82M
EPS (basic) 1.53
EPS (diluted) -26.67
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.16M
Short Ratio 11.76
Short % of Float 9.06%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.63
Revenue n/a
Operating Income -45.55M
Net Income -45.09M
Free Cash Flow n/a
Net Cash 112.68M
Net Cash / Share 5.32
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -32.16%
ROE -57.64%
ROIC 595.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 1
Overweight 1
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(37.69% upside)
Current: $26.00
Target: 35.80
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-29.54-16.49-15.85
Net Income-28.06-15.53-15.19
Shares Outstanding6.001.151.15
Earnings Per Share-4.67-13.45-13.17
Operating Cash Flow-26.71-15.25-14.00
Capital Expenditures-0.03--
Free Cash Flow-26.74-15.25-14.00
Cash & Equivalents13065.6824.40
Total Debt0.30--
Net Cash / Debt13065.6824.40
Book Value124-51.44-35.77
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aprea Therapeutics, Inc.
Country United States
Employees 13
CEO Christian S. Schade

Stock Information

Ticker Symbol APRE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: APRE
IPO Date October 3, 2019


Aprea Therapeutics, a biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate is APR-246, a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia. The company was founded in 2006 and is headquartered in Boston, Massachusetts.